drugset / Trial / NCT00004393
Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
Phase 2
Completed
50 enrolled
National Center for Research Resources (NCRR)
Yale University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
OBJECTIVES: I. Conduct a randomized, double blind, placebo controlled, parallel study of the atypical neuroleptic risperidone (RIS) in the treatment of children and adults with moderate to severe Tourette Syndrome. II. Evaluate further the safety of RIS in this population.
Timeline
- Start
- 1997-07
- Primary completion
- —
- Completion
- 2000-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risperidone | Other / unclassified | — | — |